# Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

Study · id `cardio:ct-nct02966028` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02966028](<https://clinicaltrials.gov/study/NCT02966028>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02966028

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.

## Technical summary

Registry record NCT02966028. Randomized; quadruple masking; primary purpose treatment. Start 2016-11 (registry gives no type); primary completion 2019-08 (actual). Results posted on 2021-03-16.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 274 participants (enrolled count; ClinicalTrials.gov record NCT02966028, source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)
- Start date: 2016-11 (registry gives no type) (ClinicalTrials.gov record NCT02966028, source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)
- Primary completion: 2019-08 (actual) (ClinicalTrials.gov record NCT02966028, source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)
- Completion: 2019-09 (actual) (ClinicalTrials.gov record NCT02966028, source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)
- Results first posted: 2021-03-16 (ClinicalTrials.gov record NCT02966028, source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)
- Countries: United States; Spain; United Kingdom (ClinicalTrials.gov record NCT02966028, source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02966028-2021-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
- Condition: Cardiovascular Diseases
- Condition: Cardiovascular Abnormalities
- Condition: Calcifications, Vascular
- Condition: Endstage Renal Disease
- Condition: ESRD
- Condition: Coronary Artery Calcification
- Intervention (Drug): SNF472
- Intervention (Drug): Placebo
- Lead sponsor: Sanifit Therapeutics S. A.
- Lead sponsor class: OTHER
- Collaborator: Clinipace Worldwide
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study (`cardio:pubmed-31707860`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study (`cardio:pubmed-33835939`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0a997283ef12440a499fc5decfd808b27f79c57dec32369e50f5071a8ade9e7d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
